Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®
11 févr. 2025 12h59 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma will import KODATEF® from Australia to ensure U.S. tafenoquine supply, addressing rising ARAKODA® demand.
60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
06 févr. 2025 14h07 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma closed a $1.075M registered direct offering, raising $2.118M YTD to fund operations. H.C. Wainwright & Co. acted as placement agent.
60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
05 févr. 2025 09h22 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (SXTP) announces a $1.075M registered direct offering, issuing stock and warrants to fund working capital and corporate initiatives.
60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
30 janv. 2025 14h20 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (Nasdaq: SXTP) closed a $1.043M registered direct offering, issuing common stock and short-term warrants to fund working capital.
60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
29 janv. 2025 08h00 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (SXTP) announces a $1.043M registered direct offering, issuing stock and warrants to fund working capital and corporate initiatives.
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
28 janv. 2025 08h01 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals announces IRB approval for Phase II study of tafenoquine for chronic babesiosis, with enrollment starting Q3 2025.
60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis
08 janv. 2025 08h02 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (Nasdaq: SXTP) begins enrolling patients in a clinical study to evaluate tafenoquine for persistent, relapsing babesiosis treatment.
Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
23 déc. 2024 08h57 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma and Tufts MC partner to develop tafenoquine for babesiosis, co-own patents, and aim for FDA approval to address unmet medical needs.
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
14 nov. 2024 14h31 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (SXTP) reported 164% revenue growth and clinical progress on ARAKODA® for infectious diseases and babesiosis in its 3Q24 earnings report.
60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
03 oct. 2024 09h02 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals launches a pilot to boost ARAKODA® awareness, focusing on virtual sales and a co-pay program for malaria prevention.